ICICI Prudential Asset Management Co Ltd Purchases 863 Shares of DexCom, Inc. (NASDAQ:DXCM)

ICICI Prudential Asset Management Co Ltd increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 19.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 5,231 shares of the medical device company’s stock after purchasing an additional 863 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in DexCom were worth $351,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Empowered Funds LLC boosted its stake in shares of DexCom by 30.7% in the 1st quarter. Empowered Funds LLC now owns 5,518 shares of the medical device company’s stock valued at $765,000 after purchasing an additional 1,295 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in DexCom by 10.6% in the first quarter. QRG Capital Management Inc. now owns 10,896 shares of the medical device company’s stock valued at $1,511,000 after buying an additional 1,046 shares during the period. Avantax Advisory Services Inc. boosted its stake in DexCom by 35.4% in the first quarter. Avantax Advisory Services Inc. now owns 3,601 shares of the medical device company’s stock valued at $499,000 after acquiring an additional 942 shares during the last quarter. Bleakley Financial Group LLC grew its holdings in DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after acquiring an additional 87 shares during the period. Finally, Kingsview Wealth Management LLC grew its holdings in DexCom by 4.3% during the 1st quarter. Kingsview Wealth Management LLC now owns 14,880 shares of the medical device company’s stock worth $2,064,000 after acquiring an additional 613 shares during the period. Institutional investors own 97.75% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the topic of several recent research reports. JPMorgan Chase & Co. raised their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Wells Fargo & Company lifted their price objective on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Sanford C. Bernstein increased their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. BTIG Research dropped their target price on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Finally, Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Stock Performance

Shares of DXCM opened at $72.53 on Thursday. The company has a market cap of $28.33 billion, a PE ratio of 43.43, a price-to-earnings-growth ratio of 2.28 and a beta of 1.17. The firm has a 50-day moving average of $69.72 and a 200-day moving average of $92.27. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other DexCom news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.